Showing 641-650 of 23030 results for "".
Physicians For Human Rights: How You Can Get Involved
https://reachmd.com/programs/clinicians-roundtable/physicians-for-human-rights-how-you-can-get-involved/2215/With our special skills, ethical obligations and credible voices, health professionals are in a unique position to be human rights advocates. What is being done and how can you get involved? Past president of the board of directors of Physicians for Human Rights, Dr. Holly Atkinson tells host Dr. LeClinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
https://reachmd.com/programs/cme/clinical-criteria-and-imaging-strategies-for-b7-h3directed-adcs-in-es-sclc/39977/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Robert Schimmel on Humor in Surviving Cancer
https://reachmd.com/programs/clinicians-roundtable/robert-schimmel-on-humor-in-surviving-cancer/2691/Robert Schimmel, one of Comedy Central's 100 Greatest Comics, authored Cancer on $5 a day* *chemo not included: How Humor Got Me Through the Toughest Journey of My Life. Mr. Schimmel discussed how he survived his battle with stage three non-Hodgkin's lymphoma.Balancing a Busy Career: Mentorship Session With Dr. Peter Lio
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/balancing-a-busy-career-mentorship-session-with-dr-peter-lio/48812/Peter A. Lio, MD, a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, discusses how he balances his clinical practice with his academic responsibilities, thought leadership, and more in this "Ask Me Anything" mentorship session.Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
https://reachmd.com/programs/cme/real-world-igan-a-case-based-approach-to-maximizing-kidney-preservation/26635/Are you implementing the new KDIGO guidelines for IgA nephropathy? Learn how to apply them in clinical practice using a real-world patient case.Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
https://reachmd.com/programs/cme/muscarinic-therapies-as-a-catalyst-for-change-addressing-clinical-inertia-in-schizophrenia-care/37101/Examine muscarinic modulation as an alternative to D2 antagonists for schizophrenia, with insights on dosing, tolerability, and patient selection.Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
https://reachmd.com/programs/cme/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/Experts review strategies for aggressive LDL lowering in high-risk patients without prior MI or stroke, highlighting updated targets and VESALIUS-CV data.